Atypical Hemolytic Uremic Syndrome (aHUS) Overview

Save information for later
Sign Up

Learn About Atypical Hemolytic Uremic Syndrome (aHUS)

What is the definition of Atypical Hemolytic Uremic Syndrome (aHUS)?
Atypical hemolytic uremic syndrome is a very rare disease that causes anemia due to red blood cell destruction, a low platelet count, blood clots, and acute kidney failure.
What are the symptoms of Atypical Hemolytic Uremic Syndrome (aHUS)?
Symptoms of atypical hemolytic uremic syndrome include a sudden onset, malaise, fatigue, lethargy, irritability, anemia, a low platelet count, acute kidney failure, high blood pressure, reduced blood flow and/or small blood clots in blood vessels, headaches, seizures, organ damage and failure, an enlarged heart, heart attack, gastrointestinal bleeding, swelling in the lungs, double vision, facial paralysis, stroke, and coma.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Atypical Hemolytic Uremic Syndrome (aHUS)?
Treatments for atypical hemolytic uremic syndrome include supportive care; nutritional therapy; blood transfusions; peritoneal dialysis or hemodialysis; plasma therapy; plasma exchange; medications, such as vasodilators, eculizumab, ravulizumab-cwvz, and immunosuppressants; and kidney transplantation.
Who are the top Atypical Hemolytic Uremic Syndrome (aHUS) Local Doctors?
Distinguished in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Joseph A. Readling
Hematology Oncology | Oncology | Hematology
Distinguished in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Joseph A. Readling
Hematology Oncology | Oncology | Hematology

Guthrie Medical Group PC

34 W Main St, 
Cortland, NY 
 (52.7 mi)
607-756-3130
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Readling is a Hematologist Oncology specialist and an Oncologist in Cortland, New York. Dr. Readling and is rated as a Distinguished provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). His top areas of expertise are Atypical Hemolytic Uremic Syndrome (aHUS), D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, and Paget Disease of the Breast.

Distinguished in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Maria T. Bertini
Family Medicine
Distinguished in Atypical Hemolytic Uremic Syndrome (aHUS)
Dr. Maria T. Bertini
Family Medicine

United Health Services Hospitals, Inc.

4433 Vestal Pkwy E, 
Vestal, NY 
 (55.9 mi)
607-771-2220
Experience:
16+ years
Languages Spoken:
English

Maria Bertini is a Family Medicine provider in Vestal, New York. Dr. Bertini has been practicing medicine for over 16 years and is rated as a Distinguished provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). Her top areas of expertise are D-Plus Hemolytic Uremic Syndrome, Hemolytic-Uremic Syndrome, Atypical Hemolytic Uremic Syndrome (aHUS), and Hyperlipidemia Type 3.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Atypical Hemolytic Uremic Syndrome (aHUS)
Kara L. Spalik, NP
Nurse Practitioner
Advanced in Atypical Hemolytic Uremic Syndrome (aHUS)
Kara L. Spalik, NP
Nurse Practitioner

United Health Services Hospitals, Inc.

54 Main St, 
Candor, NY 
 (37.2 mi)
607-659-7272
Languages Spoken:
English
See accepted insurances

Kara Spalik is a Nurse Practitioner in Candor, New York. Spalik and is rated as an Advanced provider by MediFind in the treatment of Atypical Hemolytic Uremic Syndrome (aHUS). Her top areas of expertise are Atypical Hemolytic Uremic Syndrome (aHUS), Smoldering Multiple Myeloma, Marginal Zone Lymphoma (MZL), and Gallbladder Adenocarcinoma.

View All Doctors
What are the latest Atypical Hemolytic Uremic Syndrome (aHUS) Clinical Trials?
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Pediatric Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Who is this study for: Patients with Atypical Hemolytic Uremic Syndrome
Enrollment Status: Recruiting
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Crovalimab
Study Phase: Phase 3

Summary: This study aims to evaluate the efficacy and safety of crovalimab in pediatric participants with aHUS.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
A Phase III, Multicenter, Single-Arm Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
Who is this study for: Adult and adolescent participants with atypical hemolytic uremic syndrome
Enrollment Status: Recruiting
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Crovalimab
Study Phase: Phase 3

Summary: This study aims to evaluate the efficacy and safety of crovalimab in adult and adolescent participants with aHUS.

View All Clinical Trials